PA2-GNU7
PA2-GNU7 is an antimicrobial peptide (AMP). PA2-GNU7 exhibits potent antimicrobial activity with minimal inhibitory concentration (MIC) against P. aeruginosa, E. coli, S. typhimurium, S. aureus, and C. albicans are 2 μM, 1 μM, 2 μM, 2 μM, and 8 μM, respectively. PA2-GNU7 rapidly and selectively kills Pseudomonas aeruginosa without affecting other commensal bacteria. PA2-GNU7 significantly improves survival of mice infected with P. aeruginosa. PA2-GNU7 can be used for the research and development of therapeutic agents against MDR Pseudomonas aeruginosa infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2387505-19-1
- 화학식: C150H276N50O37
- 분자량:3372.11
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
In Vitro
PA2-GNU7 (21 h) exhibits potent antimicrobial activity with minimal inhibitory concentration (MIC) against P. aeruginosa, E. coli, S. typhimurium, S. aureus, and C. albicans are 2 μM, 1 μM, 2 μM, 2 μM, and 8 μM, respectively[1].
PA2-GNU7 (1 μM) selectively kills P. aeruginosa in dual-species cultures (1:1 P. aeruginosa with E. coli or S. typhimurium)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (6-8 weeks old, female) infected with 2×107 CFU MDR P. aeruginosa[1]
-
Dosage:15 mg/kg or 25 mg/kg
-
Administration:Intraperitoneal injection 30 min post-infection
-
Result:Achieved significantly improved survival rates.
Reduced bacterial loads in the liver, kidney, and spleen.
Chemical Information
-
CAS No. 2387505-19-1
-
분자량 3372.11
-
화학식 C150H276N50O37
-
Sequence
Ser-Gln-Arg-Lys-Leu-Ala-Ala-Lys-Leu-Thr-Ser-Lys-Gly-Gly-Gly-Arg-Leu-Leu-Arg-Pro-Leu-Leu-Gln-Leu-Leu-Lys-Gln-Lys-Leu-Arg
-
Sequence Shortening
SQRKLAAKLTSKGGGRLLRPLLQLLKQKLR
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PA2-GNU7 Related Classifications
HY-P11091 Related Classifications
Powered by Bioz